Target intelligence / Profile preview

Conserved oligomeric Golgi complex subunit 7 (COG7)

Target
COG7
Molecular classification
Other, Cellular trafficking complex protein, CATCHR (complexes associated with tethering containing helical rods) family
01

Overview

Conserved oligomeric Golgi complex subunit 7 (COG7) is a protein encoded by the COG7 gene located on chromosome 16 (16q12.2) in humans[1][2][4]. COG7 is one of eight subunits of the conserved oligomeric Golgi (COG) complex, a multi-protein complex critical for maintaining the structure and function of the Golgi apparatus[1][3][4]. This complex mediates the tethering and fusion of vesicles carrying glycosylation enzymes and other Golgi-resident proteins, ensuring proper trafficking, localization, and modification of glycoproteins via N- and O-linked glycosylation pathways[1][2][3][4]. COG7, in association with subunits COG4, COG5, and COG6, forms part of a structural and functional core essential for these trafficking processes[3]. Mutations in COG7 or other subunits disrupt glycoprotein processing, leading to congenital disorders of glycosylation (CDG), most notably COG7-CDG, a rare, inherited multisystem disorder presenting with developmental delay, neurological dysfunction, organ involvement, and abnormal glycan structures on serum proteins[1][2]. There are currently no approved drugs targeting COG7, and it is not classified as a typical therapeutic target such as a receptor, enzyme, or transporter[1][2][3][4].

Other names
Component of oligomeric Golgi complex 7COG complex subunit 7CDG2EUNQ3082/PRO10013
02

Biological functions

Vesicular trafficking (Golgi-to-ER and intra-Golgi transport)Protein glycosylation (N- and O-linked glycosylation processing in the Golgi)Golgi apparatus structure maintenanceProtein localization to organellesProtein stabilization
03

Disease associations

Congenital disorders of glycosylation (COG7-CDG / CDG-IIe)Rare, multisystem developmental and metabolic disordersPotential "other"
04

Safety considerations

Loss of COG7 function causes severe congenital glycosylation disorder (COG7-CDG): multisystemic involvement, developmental delay, organ abnormalities, no current therapeutic options, and no gene-targeted interventions available
05

Biomarkers

Abnormal N- and O-glycan profiles (used in diagnosis of COG7-CDG; detected by glycomic screening in patient samples)Genetic testing for mutations in the COG7 gene

Beyond the preview

Go deeper on Conserved oligomeric Golgi complex subunit 7 (COG7).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Conserved oligomeric Golgi complex subunit 7 (COG7).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call